David A. Brenner, MD - Sanford Burnham Prebys

Dr. Brenner was named president and chief executive officer of Sanford Burnham Prebys in September 2022 after serving as vice chancellor for health sciences at UC San Diego and dean of its school of medicine for an unprecedented 15 years, during which he oversaw the launch and expansion of numerous multidisciplinary efforts, including the Institute for Engineering in Medicine, the Institute for Genomic Medicine, the Sanford Consortium for Regenerative Medicine, the UC San Diego Sanford Clinical Stem Cell Program, and the C3 Cancer Center Consortium (comprising UC San Diego, the Salk Institute for Biological Studies and Sanford Burnham Prebys).

Previously, he served as chair of the Department of Medicine and Physician-in-Chief of New York Presbyterian Hospital/Columbia University and, before that, as Chief of Gastroenterology and Hepatology at University of North Carolina at Chapel Hill.

As a distinguished physician-scientist, Brenner is a recognized leader in the field of gastroenterology research, with more than 200 peer-reviewed publications, two patents and ranking among Highly Cited Researchers by Web of Science and Clarivate Analytics.

He is an elected member of the National Academy of Medicine; past president of the Association of American Physicians and former editor of the journal Gastroenterology (2001 to 2006).

He is currently deputy editor of the journal PNAS Nexus.

Education and Training

1988: Fellowship, Gastroenterology, UC San Diego
1986: Fellowship, Genetics & Biochemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
1985: Intern & Residency, Internal Medicine, Yale University
1979: MD, Medicine, Yale University
1975: BS, Biology, Yale University

Awards, Honors and Recognition

2005: Fellow (FACP), American College of Physicians
1986: Bomedical Scholar, Pew Foundation

Other Appointments and Memberships

Alcoholic Beverage Medical Research Foundation
American Society for Clinical Investigation
Association of American Physicians
American College of Physicians
American Gastroenterological Association
American Clinical and Climatological Association

Related Disease
Liver Diseases

Phenomena or Processes
Apoptosis and Cell Death

Anatomical Systems and Sites
Liver

Research Models
Mouse

Clinical Trials

Alpha-1 Antitrypsin Deficiency Adult Liver Study
Start Date: Dec 2013
Estimated Completion Date: Sep 2023
Recruitment Status: Recruiting
Condition(s): Alpha-1 Antitrypsin Deficiency

Research Activities and Funding

Microbiome as Therapeutic Target in Alcoholic Hepatitis
NIHU01AA021856Jun 1, 2013 – May 31, 2019
Role: Principal Investigator
The Southern California Research Center for ALPD and Cirrhosis
NIHP50AA011999Jan 1, 1999 – Dec 31, 2023
Role: Co-Investigator
Gastroenterology Research Training
NIHT32DK007737Aug 1, 1996 – Jun 30, 2026
Role: Principal Investigator
Molecular and Cellular Pathogenesis in Alcoholism
NIHP60AA011605Dec 1, 1997 – Nov 30, 2017
Role: Co-Investigator
Molecular Mechanisms by which TNFalpha Modulates Fibrosis
NIHR01GM041804Apr 1, 1989 – Dec 31, 2014
Role: Principal Investigator
Integrated Center for InVivo Microscopy
NIHP41RR005959Sep 1, 1990 – Jun 30, 2013
Role: Co-Investigator

The Role of Inflammation and Stroma in Digestive Cancer
NIHU54CA126513Sep 30, 2006 – Sep 21, 2011
Role: Co-Investigator
Angiotensin II and NADPH Oxidase in Hepatic Fibrosis
NIHR01DK072237Sep 15, 2005 – Jun 30, 2011
Role: Principal Investigator
Hepatic Stellate Cell Activation induced by Hepatitis C Virus
NIHR01AA015055Sep 30, 2003 – Aug 31, 2009
Role: Principal Investigator
Cond. Acceptance Post-Bac. Prog. Scholarship Fund
NIHS22MD000227Sep 30, 2002 – Sep 29, 2005
Role: Principal Investigator
Molecular Pathogenesis of Apoptosis in Liver Cells
NIHP01DK059340Sep 21, 2001 – May 31, 2006
Role: Co-Investigator
Oncogenic K-Ras Induction of Gastrin Gene Transcription
NIHR01DK055686Aug 15, 2000 – Jul 31, 2006
Role: Principal Investigator
Gene Technology Therapy and Alcohol-Induced Fibrosis
NIHR01AA012586Sep 23, 1999 – Jun 30, 2003
Role: Principal Investigator
Molecular and Cellular Pathogenesis in Alcoholism
NIHP50AA011605Dec 1, 1997 – Nov 30, 2002
Role: Co-Investigator
Rat Model of Alcoholic Pancreatitis
NIHR03AA011226Apr 1, 1997 – Mar 31, 1999
Role: Principal Investigator
Gene Therapy for Liver Diseases
NIHR13DK047627Jan 20, 1994 – Oct 31, 1994
Role: Principal Investigator
Molecular Defects in Protoporphyria
NIHR01DK047361May 1, 1993 – May 31, 2004
Role: Principal Investigator
Function of Nuclear Oncogenes in Cancer Cells
NIHP01CA050528Sep 8, 1989 – Jan 31, 1998
Role: Co-Investigator
Molecular Defect in Protoporphyria
NIHR29DK039996Apr 1, 1988 – Mar 31, 1993
Role: Principal Investigator
General Clinical Research Center
NIHM01RR000827Mar 1, 1974 – Nov 30, 2010
Role: Principal Investigator

Select Publications

Showing 3 of 3

Alternatives to animal testing to assess MASH drugs and hepatotoxicity.

Brenner DA

Hepatology 2023 Nov 6 ;():

Ischemic Stroke in a Seven-Year-Old Female With Down Syndrome and Newly Discovered Moyamoya Syndrome.

Brenner DA, Flatley E, Medappa Maruvanda S, Dadario NB, Valdivia DJ, Khosla M

Cureus 2023 Sep ;15(9):e45893

Compact engineered human mechanosensitive transactivation modules enable potent and versatile synthetic transcriptional control.

Mahata B, Cabrera A, Brenner DA, Guerra-Resendez RS, Li J, Goell J, Wang K, Guo Y, Escobar M, Parthasarathy AK, Szadowski H, Bedford G, Reed DR, Kim S, Hilton IB

Nat Methods 2023 Nov ;20(11):1716-1728

View All Publications

We translate science into health

The path to better knowledge starts here

You can help fund the next breakthrough

Dedicated to human disease and advancing discoveries.

Global Search

Education and Training

Awards, Honors and Recognition

Other Appointments and Memberships

Clinical Trials

Research Activities and Funding

Select Publications

Alternatives to animal testing to assess MASH drugs and hepatotoxicity.

Ischemic Stroke in a Seven-Year-Old Female With Down Syndrome and Newly Discovered Moyamoya Syndrome.

Compact engineered human mechanosensitive transactivation modules enable potent and versatile synthetic transcriptional control.

Biography

Education and Training

Awards, Honors and Recognition

Other Appointments and Memberships

Research

Select Publications

Alternatives to animal testing to assess MASH drugs and hepatotoxicity.

Ischemic Stroke in a Seven-Year-Old Female With Down Syndrome and Newly Discovered Moyamoya Syndrome.

Compact engineered human mechanosensitive transactivation modules enable potent and versatile synthetic transcriptional control.